Rashmi Kanagal-Shamanna

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Rashmi Kanagal-Shamanna
Feb 27, 2025, 11:09 | Science
Nitin Jain: Treatment-free remission in Ph+ ALL
Nitin Jain, Professor of Medicine at The University of Texas MD Anderson Cancer Center, shared…
Feb 26, 2025, 16:33 | Science
Hagop Kantarjian: Treatment-free remission in non-transplanted Ph+ ALL patients
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Jan 29, 2025, 18:14 | Science
Charles Gaulin: Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma
Charles Gaulin, Hematologic Oncologist at Dartmouth Hitchcock Medical Center and Clinics, shared his recent article…
Dec 26, 2024, 14:37 | Insight
Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “Check…
Dec 26, 2024, 13:03 | Insight
Naveen Pemmaraju: Diagnostic challenges of high-grade myeloid malignancies
Naveen Pemmaraju, Director of BPDCN Program at the Department of Leukemia at the University of…
Jul 23, 2024, 22:30 | Blog
Hagop Kantarjian: The simultaneous combination of ponatinib and blinatumomab highly effective
Hagop Kantarjian shared on X: "The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate…
Dec 26, 2023, 13:18 | Insight
Sanam Loghavi: How we apply WHO in the Diagnosis and classification of myeloid neoplasms in practice
Sanam Loghavi shared a post on LinkedIn: ''On behalf of the WHO 5th Edition Classification…
All: 7 Posts: 1 - 100
Special Coverage